European Neuroendocrine Tumor Society ( ENETS ) 2023 guidance paper for digestive neuroendocrine carcinoma
Journal of Neuroendocrinology · 2023-03 · 35 (3)
DOI: 10.1111/jne.13249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuroendocrinology, online erschienen am 16.03.2023. Verfasst von Halfdan Sorbye und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 205-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This ENETS guidance paper, developed by a multidisciplinary working group, provides up‐to‐date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma, based on recent developments and study results. These recommendations aim to pave the road for more standardized care for our patients resulting in improved outcomes. Prognosis is generally poor for digestive NEC, most are advanced at diagnosis and median survival in metastatic disease is 11–12 months. Surgery can be of benefit for localized disease after extensive preoperative imaging. Carboplatin in combination with etoposide is recommended as first‐line treatment for metastatic disease. Irinotecan with fluoropyrimidines has the best evidence as second‐line treatment. Immunotherapy plays a minor role in biomarker‐unselected patients. Molecular profiling if available is encouraged to identify new targets. More prospective clinical trials are highly needed to fulfil the unmet needs in this field, especially on new predictive and prognostic biomarkers and to improve survival of patients with advanced disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Norway.
- Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain.
- Department of Medicine 1, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
- Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy.
- Department of Clinical Oncology, Beatson Oncology Center, Glasgow, UK.
ORCID-Profile: Halfdan Sorbye, Nicholas Simon Reed
Zitieren
APA
Sorbye, H., Grande, E., Pavel, M., Tesselaar, M., Fazio, N., Reed, N. S., Knigge, U., Christ, E., Ambrosini, V., Couvelard, A., & Tiensuu Janson, E. (2023). European Neuroendocrine Tumor Society ( ENETS ) 2023 guidance paper for digestive neuroendocrine carcinoma. Journal of Neuroendocrinology, 35(3). https://doi.org/10.1111/jne.13249
Vancouver
Sorbye H, Grande E, Pavel M, Tesselaar M, Fazio N, Reed NS, et al. European Neuroendocrine Tumor Society ( ENETS ) 2023 guidance paper for digestive neuroendocrine carcinoma. Journal of Neuroendocrinology. 2023;35(3). doi:10.1111/jne.13249
BibTeX
@article{Sorbye2023,
author = {Sorbye, Halfdan and Grande, Enrique and Pavel, Marianne and Tesselaar, Margot and Fazio, Nicola and Reed, Nicholas Simon and Knigge, Ulrich and Christ, Emanuel and Ambrosini, Valentina and Couvelard, Anne and Tiensuu Janson, Eva},
title = {European Neuroendocrine Tumor Society ( ENETS ) 2023 guidance paper for digestive neuroendocrine carcinoma},
journal = {Journal of Neuroendocrinology},
year = {2023},
volume = {35},
number = {3},
doi = {10.1111/jne.13249}
}
EUVIMED